An analyst who gives a stock an overweight rating expects the stock's price to outperform its industry in the future. The ...
15d
JPMorgan Initiates Hims & Hers With Overweight: Could the Novo Nordisk Deal Be the Turning Point?
Hims & Hers Health (NYSE:HIMS) just picked up a high-profile endorsement. JPMorgan analyst Cory Carpenter initiated coverage with an Overweight rating and a $35 price target, framing the telehealth ...
Zoetis Inc. (NYSE:ZTS) ranks among the best medical stocks to buy according to analysts. With a price target of $210, Piper Sandler reaffirmed its Overweight rating on Zoetis Inc. (NYSE:ZTS) on July 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results